Pharmacokinetics and acute tolerance of a double virus inactivated plasma derived factor VIII concentrate

Haemophilia

Volumn 5, Issue 4, 1999, Pages 260-265

  Saez, A ^a   Bosh, N ^a   Boadas, N ^a   Arguello, A ^a   Horvat, D ^b   Dinapoli, G ^b   Lisciani, R ^c  

^a Banco Munic Sangre Distrito F   (Venezuela)

^b ISI SpA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acute tolerance; Factor VIII pharmacokinetics; Virus inactivating procedures

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE;

ADOLESCENT; ADULT; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TOLERANCE; HEAT TREATMENT; HEMOPHILIA A; HEPATITIS A VIRUS; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS INACTIVATION; VIRUS INFECTION; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; BLOOD COMPONENT TRANSFUSION; BLOOD PHYSIOLOGY; CONSUMER PRODUCT SAFETY; CROSS-OVER STUDIES; DETERGENTS; DISEASE TRANSMISSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VIII; FREEZE DRYING; HALF-LIFE; HEAT; HUMANS; MALE; MIDDLE AGED; RANDOM ALLOCATION; SOLVENTS; TEMPERATURE;

EID: 0032878362     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1999.00290.x     Document Type: Article

References (22)

1. Edwards CA, Piet MPJ, Chin S, Horowitz B. Tri(n-Butyl) Phosphate/Detergent treatment of licensed therapeutic and experimental blood derivatives. Vox Sang 1987; 52: 53-9.
2. Horowitz B. Investigations into the application of tri(n-butyl) phosphate/detergent mixtures to blood derivatives. In Morgentaler JJ, Ed. Virus Inactivation in Plasma Products. Current Studies in Haematology and Blood Transfusion. S. Karger Publishers, Basel, No. 56, 1989, pp. 83-96.
3. Gerritsen A, Schneweis KE, Brakmann HH. Acute hepatitis A in haemophiliacs. Lancet 1992; 340: 1231-2.
4. Robinson DM, Schwinn H, Smith A. Clotting factors and hepatitis A. Lancet 1992; 340: 1465.
5. Temperly IJ, Cotter KP, Walsh TJ, Power J, Hillary IB. Clotting factors and hepatitis A. Lancet 1992; 340: 1466.
6. Mannucci PM. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates. Vox Sang 1993; 64: 197-203.
7. Peerlink K, Vermylen J. Acute hepatitis A in patients with haemophilia A. Lancet 1993; 341: 179.
8. Di Paolantonio T, Mariani G, Ghirardini A, et al. Low risk of transmission of the human immunodeficiency virus by a solvent-detergent treated commercial factor VIII concentrate. J Med Virol 1992; 36: 71-4.
9. Mariani G, Di Paolantonio T, Baklaja R, Mannucci PM. Prospective hepatitis C safety evaluation of a high-purity solvent/detergent treated FVIII concentrate. Blood 1991; 78S: 55 (Abstract).
10. Pistello M, Ceccherini-Nelli L, Cecconi N, Bendinelli M, Panicucci F. Hepatitis C virus seroprevalence in Italian haemophiliacs injected with virus-inactivated concentrates: five years follow-up and correlation with antibodies to other viruses. J Med Virol 1991; 33: 43-6.
11. Mannucci PM. Outbreak of hepatitis A among Italian patients with haemophilia. Lancet 1992; 339: 819.
12. Franco E, Divizia M, De Santis ME, Azzi A, Arrighi S, Borri MG. Inactivation of non-lipid enveloped viruses by dry-heat treatment of factor VIII concentrates. Lecture delivered at Virological Safety Aspects of Plasma Derivatives. International Association of Biological Standardization, Cannes, France, November 3-6, 1992.
13. Tradati F, Santagostino E, Gringeri A, et al. No hepatitis virus transmission by double-inactivated (solvent/detergent plus terminal super-dry heating) concentrates. Thromb Haemost 1995; 73: 484.
14. Santagostino E. Safety Study of a Double-inactivated High-purity Concentrate: Results of a Very Long Follow-up Period. Lecture delivered at: International Symposium on Thrombosis Haemostasis and Vascular Biology, Porto, Portugal, June 17-19, 1996.
15. Kjellman H. Calculations of factor VIII in vivo recovery and half-life. Scand J Haematol 1984; 33: 165-174.
16. Chow Shein-Chung, Liu Jen-pei. Design and analysis of bioavailability and bioequivalence studies. Marcel Dekker Inc. Publisher, New York, 1992.
17. Morfini M, Ciavarella N, Paolini R, et al. Pharmacokinetics of a New Double Treated FVIII Concentrate. Lecture delivered at XXI International Congress of the World Federation of Haemophilia, Abstract 212, 1994.
18. Saez A, Boadas A, Bosh N, et al. Pharmacokinetic and tolerance comparative study of two virus inactivated FVIII concentrates. Lecture delivered at XXI International Congress of the World Federation of Haemophilia, Abstract 214, 1994.
19. Arrighi S, Rossi R, Borri MG, et al. In vitro and in animal model studies on a double virus-inactivated Factor VIII concentrate. Thromb Haemost 1995; 74: 868-73.
20. Ciavarella N, Lattarulo M, Schiavoni M, Mendolicchio L. Surveillance of inhibitor formation in haemophilia A patients treated with a double virus inactivated purified preparation of factor VIII: A retrospective study of Emoclot DI. Lecture delivered at the XIV International Symposium on Thrombosis Haemostasis and Vascular Biology, Porto, Portugal, 17-19 June, 1996.
21. Mariani G, Di Paolantonio T, Baklaya R, Morfini M, Mannucci PM. Prospective study of the evaluation of hepatitis C virus infectivity in a high-purity, solvent/ detergent-treated factor VIII concentrate: parallel evaluation of other markers for lipid-enveloped and non-lipid enveloped viruses. Transfusion 1993; 33: 814-18.
22. Williamson J. Factor VIII validation/removal during the manufacturing process of factor VIII Inveresk Research unpublished report no 13319, 1997.